Subscribe

Stay Informed. Stay Ahead.

Subscribe to receive curated updates, expert insights, and practical education—delivered straight to your inbox.

Get timely coverage on new approvals, case-based discussions, conference highlights, and practical tools for everyday practice in community oncology and hematology.

Subscribe
*
Skip to main content
OncUpdates
  • Conferences
    • ASCO GU
    • ASCO GI
    • ASH
    • SABCS
    • ESMO
    • WCLC
    • ASCO
  • Videos & Podcasts
    • Challenging Cases
      • Hematology
      • Lung Cancer
      • Breast Cancer
      • GU Oncology
    • New Approvals
      • Hematology
      • GI Oncology
      • GU Oncology
      • Lung Cancer
      • Breast Cancer
    • Tox Check
      • GI Oncology
      • GU Oncology
      • Lung Cancer
      • Breast Cancer
      • Hematology
    • Treatment Algorithms
      • Breast Cancer
      • Dermatology
      • Hematology
      • Lung Cancer
      • Ovarian Cancer
      • Head and Neck Cancers
  • Clinical Insights
    • GU Oncology
      • Bladder Cancer
      • RCC
    • GI Oncology
      • Gastroesophageal Cancer
      • Gastric/GEJ Cancer
    • Breast Cancer
      • Early HR+
      • Metastatic HR+
    • Hematology
      • Polycythemia Vera
    • Lung Cancer
      • SCLC
      • NSCLC
  • Resource Centers
    • Pancreatic Cancer
    • Metastatic Breast Cancer
  • Articles
    • GI Oncology
    • Hematology
    • Lung Cancer
  • Events
  • Conferences
    • ASCO GU
    • ASCO GI
    • ASH
    • SABCS
    • ESMO
    • WCLC
    • ASCO
  • Videos & Podcasts
    • Challenging Cases
      • Hematology
      • Lung Cancer
      • Breast Cancer
      • GU Oncology
    • New Approvals
      • Hematology
      • GI Oncology
      • GU Oncology
      • Lung Cancer
      • Breast Cancer
    • Tox Check
      • GI Oncology
      • GU Oncology
      • Lung Cancer
      • Breast Cancer
      • Hematology
    • Treatment Algorithms
      • Breast Cancer
      • Dermatology
      • Hematology
      • Lung Cancer
      • Ovarian Cancer
      • Head and Neck Cancers
  • Clinical Insights
    • GU Oncology
      • Bladder Cancer
      • RCC
    • GI Oncology
      • Gastroesophageal Cancer
      • Gastric/GEJ Cancer
    • Breast Cancer
      • Early HR+
      • Metastatic HR+
    • Hematology
      • Polycythemia Vera
    • Lung Cancer
      • SCLC
      • NSCLC
  • Resource Centers
    • Pancreatic Cancer
    • Metastatic Breast Cancer
  • Articles
    • GI Oncology
    • Hematology
    • Lung Cancer
  • Events

Explore Videos, Articles & More

Breast Cancer

Clinical highlights, expert perspectives, and pivotal data from the ASCO breast cancer sessions, showcasing emerging evidence and advancing therapeutic strategies.

Home / Conferences / ASCO / Breast Cancer
Updates in Breast Cancer From ASCO 2025
Updates in Breast Cancer From ASCO 2025

Zunairah Shah, MD

5 Key Breast Cancer Clinical Trials Shaping Treatment
5 Key Breast Cancer Clinical Trials Shaping Treatment

Erika Hamilton, MD, FASCO, Sarah Cannon Research Institute

Clinical Impact of DESTINY-Breast09 in HER2+ Breast Cancer Management
Clinical Impact of DESTINY-Breast09 in HER2+ Breast Cancer Management

Arya Mariam Roy, MD, Hope Rugo, MD, FASCO

Strategic Timing for Multidisciplinary Care in Breast Cancer
Strategic Timing for Multidisciplinary Care in Breast Cancer

Jasmin Hundal, MD, Matthew Kurian, MD

Advancements in Oncology at ASCO 2025: Breast Cancer Highlights
Advancements in Oncology at ASCO 2025: Breast Cancer Highlights

Tanmayi Pai, MD

Key Takeaways From ASCO 2025 for Hormone-Receptor+ Metastatic Breast Cancer
Key Takeaways From ASCO 2025 for Hormone-Receptor+ Metastatic Breast Cancer

Komal Jhaveri, MD, FACP, Matthew Kurian, MD

Integrating Metastatic Triple-Negative Breast Cancer NCCN Guidelines Into Clinical Practice
Integrating Metastatic Triple-Negative Breast Cancer NCCN Guidelines Into Clinical Practice

Arya Mariam Roy, MD, Hope Rugo, MD, FASCO

ASCENT-04 Trial: First-Line Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1+ TNBC
ASCENT-04 Trial: First-Line Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1+ TNBC

Arya Mariam Roy, MD, Hope Rugo, MD, FASCO

OncUpdates

Empowering oncology professionals with The latest insights, breakthroughs, And expert opinions

Quick Links

  • About Us
  • Upcoming Events
  • Follow on X
  • Follow on LinkedIn
  • Follow on YouTube

Legal

  • Terms of Use
  • Privacy Policy
  • Cookie Settings
  • Authors
  • Contact Us

Subscribe to Our Newsletters


Property of SignifyMD LLC, All Rights Reserved 2026 SignifyMD LLC PO Box 512, Brielle, NJ 08730


Oncology Resources | Hematology Support | Community Oncology